SNRPD2

Across TCGA pan-cancer cohorts, SNRPD2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SNRPD2 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SNRPD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SNRPD2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

HNSC, LSCC, and CCRCC are the cancer types where SNRPD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	IV	0.479	0.830	.005	60	view →
LSCC	DFS	Quartile	II,III,IV	0.866	0.444	.011	11	view →
CCRCC	OS	Median	II,III,IV	0.554	1.000	.025	1	view →
GBM	OS	Tertile	All	0.499	0.294	.043	1	view →
LUAD	OS	Median	All	0.964	0.792	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SNRPD2–HNSC (DFS)

Open the HNSC breakdown →